[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"idiopathic-hyperaldosteronism\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:idiopathic-hyperaldosteronism":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100618177","superselective-adrenal-arterial-embolization-versus-oral-spironolactone-for-treatment-of-idiopathic-hyperaldosteronism-100618177",false,"NCT07328230","Superselective Adrenal Arterial Embolization Versus Oral Spironolactone for Treatment of Idiopathic Hyperaldosteronism","A Prospective Randomized Controlled Trial for Treatment of Idiopathic Hyperaldosteronism: Superselective Adrenal Arterial Embolization Versus Oral Spironolactone","Inclusion Criteria:\n\n1. Aged from 15 to 60 with no limits in sex;\n2. Patients are diagnosed with primary aldosteronism according to the criteria of the 2016 Endocrine Society guidelines;\n3. Sub-typing diagnosis confirmed idiopathic hyperaldosteronism;\n4. Patients or their legal representatives have to sign written informed consent approved by the ethics committee.\n\nExclusion Criteria:\n\n1. Unilateral adrenal hyperplasia;\n2. Renal insufficiency with an estimated glomerular filtration rate (based on the modification of diet in renal disease criteria) \\\u003C45 ml\u002Fmin\u002F1.73 m², and\u002For serum creatinine \\>176 μmol\u002FL；\n3. Hemorrhagic or ischemic stroke, endovascular stent implantation and myocardial infarction within the previous 3 months;\n4. Severe contrast agent allergy;\n5. Women who are pregnant or planning to become pregnant;\n6. Patients with other serious organic diseases cannot tolerate SAAE treatment;\n7. Other forms of secondary hypertension.","ALL","15 Years","60 Years",{"count":20,"type":21},172,"ESTIMATED","INTERVENTIONAL",[24],"NA","Idiopathic hyperaldosteronism (IHA) represents about 65% of primary hyperaldosteronism cases. Although mineralocorticoid receptor antagonists (MRAs) are the standard first-line treatment, they are often limited by adverse effects. Superselective adrenal artery embolization (SAAE) has been utilized for IHA over the last decade, yet comparative studies against MRAs are lacking. The objective of this study is to compare the safety and efficacy of SAAE and MRA to determine the feasibility of SAAE in treating IHA.",[27,28],"Idiopathic Hyperaldosteronism","Hyperaldosteronism",[30,31,28,32,33],"Superselective adrenal arterial embolization","Spironolactone","Hypertension","Mineralocorticoid receptor antagonists(","RECRUITING","2025-12-26",{"date":37,"type":38},"2026-01-09","ACTUAL",{"date":40,"type":38},"2022-08-01",{"date":42,"type":21},"2025-12-31",{"name":44,"class":45},"Chinese Academy of Medical Sciences, Fuwai Hospital","OTHER",3,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":5},"100595038","petal-trial-impact-of-gallium-68-pentixafor-pet-ct-on-surgical-outcomes-in-primary-aldosteronism-100595038","NCT07027254","PETAL Trial: Impact of Gallium-68 Pentixafor PET-CT on Surgical Outcomes in Primary Aldosteronism","A Randomized Controlled Trial to Evaluate the Effect of Gallium-68 Pentixafor PET-CT on Surgical Outcomes in Patients With Primary Aldosteronism (The PETAL Trial)","Inclusion Criteria:\n\n* Age ≥19 years\n* Diagnosed with PA per 2016 Endocrine Society guidelines\n* Underwent adrenal CT\n* Signed informed consent\n\nExclusion Criteria:\n\n* Women who are pregnant, breastfeeding, or may become pregnant\n* Individuals who refuse to undergo surgery\n* Individuals for whom 68Ga-Pentixafor PET\u002FCT, 11C-Metomidate PET\u002FCT, or adrenal venous sampling (AVS) is not feasible or is refused due to underlying conditions\n* Individuals who refuse or experience adverse effects from dexamethasone premedication required for 11C-Metomidate PET\u002FCT\n* Individuals with a history of abdominal open surgery or retroperitoneal surgery on the same side as the planned adrenalectomy\n* Any individual deemed unsuitable for the study at the discretion of the investigator","19 Years",{"count":56,"type":21},90,[24],"This study is a randomized controlled trial to assess the clinical utility of gallium-68 pentixafor PET\u002FCT in the management of primary aldosteronism (PA). We aim to evaluate whether the addition of 68Ga-pentixafor PET\u002FCT to standard adrenal venous sampling (AVS) improves surgical outcomes in patients with unilateral PA.",[60,61,62,27,63],"Primary Aldosteronism","Secondary Hypertension","Aldosterone-Producing Adenoma","Adrenalectomy",[65,66,67,68,69,70,71,63],"Primary aldosteronism","Gallium-68 pentixafor","11C-metomidate","PET\u002FCT","adrenal venous sampling","PASO","PAMO","2025-06-16",{"date":74,"type":38},"2025-06-18",{"date":76,"type":21},"2025-06-25",{"date":78,"type":21},"2027-12-01",{"name":80,"class":45},"Seoul National University Hospital"]